Jürgensmeier, J. M. (2013). KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Citação norma ChicagoJürgensmeier, Juliane M. KRAS Mutations Are Associated With Inferior Clinical Outcome in Patients With Metastatic Colorectal Cancer, but Are Not Predictive for Benefit With Cediranib. 2013.
Citação norma MLAJürgensmeier, Juliane M. KRAS Mutations Are Associated With Inferior Clinical Outcome in Patients With Metastatic Colorectal Cancer, but Are Not Predictive for Benefit With Cediranib. 2013.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.